🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — April 03, 2026

A cluster of five micro-cap companies across tech, AI, biotech, and marine sectors received delisting deficiency notices from Nasdaq and NYSE American between March 31 and April 2, 2026, signaling acute listing compliance pressures amid sustained low bid prices, equity shortfalls, and market value deficiencies. Common themes include bid price failures below $1 for 30 consecutive business days (e.g., Twin Vee post-1-for-10 reverse split in April 2025), stockholders' equity deficits (Matinas at $4.83M below $2M-$6M thresholds with 5-year losses; AEON at -$55M deficit with losses in 3/4 years), and MVPHS/MVLS shortfalls (Arrive AI below $15M/$50M). No positive period-over-period financial trends evident; instead, prolonged deficiencies (e.g., Aeries initial notice September 2025) indicate deteriorating compliance trajectories with no YoY equity recovery or bid price stabilization. All firms plan appeals or compliance plans, but ineligibility for extensions (e.g., Twin Vee, Aeries) heightens delisting risks, potentially leading to trading halts, OTC transfers, and shareholder value erosion. Portfolio-level pattern: 5/5 companies show negative sentiment (4/5 outright negative, 1 mixed), with biotechs overrepresented in equity failures; investors face liquidity risks in small caps. Critical implication: Imminent catalyst calendar of hearings and plans could trigger suspensions, advising avoidance or short positioning.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 03, 2026

The 39 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in exchange compliance failures, with 5 companies (Aeries Technology, Twin Vee PowerCats, Matinas BioPharma, Arrive AI, AEON Biopharma) receiving delisting notices due to bid price, MVPHS/MVLS, and stockholders' equity deficits below $2M-$6M thresholds as of Dec 31, 2025, signaling acute distress in microcap/biotech names. Covenant waivers and amendments dominate (United Homes, Firefly Aerospace, Fluence Energy, KORU Medical), often tied to mergers or liquidity covenants, providing short-term relief but with strings like refinancing deadlines (e.g., May 31, 2026 for United Homes). Positive offsets include M&A (Aurinia/Kezar merger Q2 2026, Forian $68M buyout, Soluna wind farm acquisition), debt cancellations (Nukkleus $16M), and equity raises (Entera Bio $10M, Vivos $4M), though many are dilutive (Mobix Labs 15% discount convertible, Interactive Strength Series C issuance). No uniform YoY/QoQ trends due to event-driven filings, but recurring low equity ($4.83M Matinas vs $6M req, -$55M AEON) and reverse splits (FibroBiologics 1:20) highlight deteriorating balance sheets. Portfolio-level: 15/39 negative/mixed sentiment, clustered in biotechs/small caps; implications include elevated bankruptcy risk but alpha in merger-arbitrage and post-financing turnarounds.

39 high priority 39 total filings
· daily

US Executive Officer Management Changes SEC — April 03, 2026

Across 38 SEC filings on US executive and director changes from April 3, 2026, the dominant theme is high turnover with over 25 resignations/departures (mostly directors and CFOs) stated as not due to disagreements, indicating routine board refreshes rather than operational distress; healthcare/biotech saw 9 events (e.g., COO death at HeartSciences, CFO appointments). Positive retention signals in 7 filings include $41.5M LTRP at MercadoLibre, $5M+ equity awards at ETHZilla, and $528k bonuses at Gibraltar, with no performance declines reported across multiple firms. Negative outliers include covenant breach threats and COO termination at Atlantic International (debt <$50M disputed as satisfied) and Intel's CLO exit. Period-over-period trends show stable metrics (no YoY/QoQ declines noted in 15+ filings), with forward-looking stability via reaffirmed guidance at WW International and 2026 bonus metrics at MercadoLibre. Portfolio implications: small-cap leadership stability supports hold; monitor finance/healthcare for transition risks amid neutral sentiment (26/38 neutral).

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 03, 2026

Across 38 SEC filings on USA Board Room Changes dated around April 3, 2026, the dominant theme is leadership stability amid 25+ neutral resignations (explicitly not due to disagreements), balanced by 10+ appointments/promotions and retention incentives like equity awards totaling $46M+ (e.g., MercadoLibre LTRP $41.5M, ETHZilla CEO $4.3M). Positive developments in 7 filings highlight management alignment via bonuses (Gibraltar $528K total), option repricings (Skye 2.42M shares), and experienced hires (e.g., Rhythm's Kim Popovits with 40+ years biotech), while negatives are limited to 2 cases: Atlantic's default notices threatening management replacement and HeartSciences COO death. No broad period-over-period deteriorations reported (e.g., 'no performance declines' in 5 filings), with forward-looking reaffirmations (WW guidance intact) signaling continuity; healthcare/biotech shows 8 changes vs tech/finance 12, implying sector-neutral churn. Portfolio-level, 70% neutral sentiment suggests low disruption risk, but high materiality (avg 6/10) in C-suite shifts warrants monitoring for execution gaps. Implications: Bullish for retention-focused firms, cautious on small-caps with disputes.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — April 03, 2026

The six SPAC filings reveal a bifurcated US M&A landscape with fresh momentum in de-SPAC transactions and IPOs contrasted by compliance distress and financing strains; Crown Reserve's Carvix merger and Future Money's $115.6M IPO (including $112M public + $3.04M private placement) signal robust deal activity, while JENA's NYSE non-compliance and DMII's sponsor transition highlight sector headwinds. No explicit YoY/QoQ financial trends or operational metrics reported across filings, but forward-looking timelines cluster catalysts in 45 days (JENA plan), 4-6 months (DMII deal execution), and 3-year earnouts (Crown). Insider activity absent; capital allocation focused on trust deposits (Future Money) and debt amendments (Inflection Point note up 14% QoQ from $700k to $800k). High materiality developments (avg 7.5/10) underscore SPAC revival potential amid regulatory risks, with positive sentiment in 2/6 filings driving takeover opportunities. Portfolio-level pattern: 4/6 newly published filings show financing/de-SPAC urgency, implying accelerated M&A timelines versus stagnant peers.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 03, 2026

Overnight SEC filings reveal a proxy season kickoff with 15+ companies scheduling May 2026 annual meetings for director elections, auditor ratifications, and say-on-pay votes, largely neutral but signaling governance stability amid mixed small-cap earnings. Period-over-period trends show revenue growth in outliers like EACO (+17.7% YoY Q2 sales to $117.8M, +44.9% NI), Karman Holdings (+36.6% FY2025 rev to $471.5M), and GE Vernova (+9% rev to $38B, +213% NI to $4.9B), but margin compression in 5/10 reporting firms (e.g., Karman -2.9 pts to 15.5%, BT Brands EBITDA +138% despite rev -9%). Capital allocation highlights shareholder returns at GEV (dividend doubled to $2/share, buybacks auth +$4B to $10B) and Alta Equipment ($0.625/dividend on preferred). M&A/spin-off catalysts include First Tracks spin-off (Apr 20 distro), European Wax going-private vote (May 7), and Lisata tender extension to Apr 13. Risks cluster around debt disputes (Atlantic International lawsuit) and covenant waivers (United Homes merger-pending), while positives emerge in licensing (OSR $815M milestones) and transformations (Super League debt-free, Q1 2026 rev beat expected). Portfolio implications favor monitoring defense/healthtech growth and May proxy-driven volatility, with small-cap mixed results tempering broad rallies.

13 high priority 21 medium 34 total filings
· daily

Federal Construction & Infrastructure Contracts — April 02, 2026

NIH's $115M award to Hensel Phelps for the Building B Vivarium Project underscores sustained federal investment in biomedical infrastructure, with full obligation met and $119M outlayed signaling project momentum. Firm-fixed price terms expose the contractor to cost overrun risks, as evidenced by outlays exceeding obligations by $4M. Potential extension to 2025-03-28 offers upside amid NIH's ongoing vivarium needs.

1 total filings
· daily

New Federal Contractors — April 02, 2026

Two new federal contract obligations totaling $352.8M signal bullish momentum in health-related IT services and construction, with VA awarding $237.7M (potential $862.8M ceiling) to SoldierPoint Digital Health and NIH $115.1M to Hensel Phelps amid $119M outlays. Firm fixed price terms introduce cost overrun risks, but options and extensions offer $500M+ upside. Investors should prioritize monitoring outlay ramps and performance extensions in federal health infrastructure spend.

2 total filings
· daily

Significant Contract Modifications ($10M+) — April 02, 2026

Two significant contract modifications totaling $352.8M signal bullish momentum in government health-related spending, with SoldierPoint's $237.7M VA IT award offering $625M upside via options and Hensel Phelps' $115.1M NIH construction deal showing $119M outlays amid potential extensions. Firm fixed price structures introduce execution risks but highlight stable revenue potential through 2029. Investors should prioritize healthcare IT and biomedical construction for near-term growth amid federal budget priorities.

2 total filings
· daily

Contract Deobligations Alert — April 02, 2026

Two bullish federal contract obligations totaling $352.8M highlight sustained U.S. government investment in healthcare infrastructure and digital health IT, with SoldierPoint's $237.7M VA award offering $625M upside via options to $862.8M ceiling. Hensel Phelps' $115.1M NIH vivarium construction shows strong execution ($119M outlays) but early overrun signals. FFP structures introduce execution risks, warranting close monitoring of option exercises and extensions amid $0-119M outlay variance.

2 total filings
· daily

Contract Option Exercises — April 02, 2026

Two bullish contract exercises totaling $352.8M obligated value highlight sustained U.S. government demand for health infrastructure, with SoldierPoint Digital Health securing $237.7M VA IT services (upside to $862.8M) and Hensel Phelps awarded $115.1M NIH vivarium construction. Both firm-fixed-price delivery orders via full/open competition signal revenue visibility for non-small businesses, though FFP structures expose cost overrun risks. Investors should prioritize monitoring option exercises and extensions amid zero outlays (SoldierPoint) and excess outlays (Hensel Phelps).

2 total filings
· daily

Federal IT & Cybersecurity Contracts — April 02, 2026

SoldierPoint Digital Health, LLC won a $237.7M obligated VA delivery order for IT architecture and application development (NAICS 541512), with base + options ceiling of $862.8M through potential 2029. This underscores robust federal healthcare IT demand but carries execution risks from firm-fixed pricing and $58.9M in subawards with zero outlays to date. Investors should monitor option exercises for revenue upside amid subcontractor dependencies.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 02, 2026

Two bullish mega-contracts totaling $353M highlight sustained federal demand for health-related IT services and biomedical construction, with SoldierPoint's $238M VA award (potential $863M) offering massive upside via options and Hensel Phelps' $115M NIH project showing strong cash flow ($119M outlaid). Firm-fixed-price structures introduce execution risks, but no bearish signals emerge. Investors should monitor option exercises and outlay ramps for revenue acceleration in gov-health sectors.

2 total filings
· daily

High-Value Federal Grants ($5M+) — April 02, 2026

Two high-value federal contracts totaling $353M obligated value signal robust demand for health infrastructure, with VA awarding $238M (potential $863M ceiling) to SoldierPoint for IT services and NIH $115M to Hensel Phelps for vivarium construction. Both firm-fixed-price deals to non-small businesses via open competition underscore bullish execution momentum amid $119M outlays already for Hensel Phelps, though FFP structures amplify cost overrun risks. Cross-cutting upside lies in $625M potential options/extensions through 2029, prioritizing health IT and biomedical facilities.

2 total filings
· daily

General Federal Contracts — April 02, 2026

Two bullish federal contracts totaling $353M underscore sustained HHS/VA investment in healthcare digital infrastructure ($238M obligated, $863M potential) and biomedical facilities construction ($115M). Firm fixed price structures expose contractors to cost overrun risks, with SoldierPoint showing no outlays yet and Hensel Phelps outlays exceeding obligations by 3%. Cross-cutting opportunities lie in option exercises and extensions to 2029, signaling multi-year revenue ramps for non-small business contractors.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 02, 2026

The 22 filings from USA S&P 500 Technology stream (April 2, 2026) are dominated by 10 proxy-related documents (DEF 14A/DEFA14A) for May 2026 AGMs, reflecting routine governance with neutral sentiment across NCS Multistage, Iridium, Radian Group, Apple Hospitality REIT, and Community Health Systems; no major disputes or declines noted. Executive transitions in 5 companies (Optimum Communications EVP demotion/retirement with $3.6M payout, Zoom COO resignation May 8, Broadcom CFO retirement Jun 12 with Alphabet CAO successor, Esquire director health-related exit, CareView ongoing debt amendments) are neutral, signaling stable leadership changes without disagreements. Positive financing and operational highlights include ISQ Open Infrastructure's $28.3M unregistered equity raise and $0.34/share distribution (May 5), Immunic's Phase 3 enrollment completion (2,221 patients, topline end-2026), CHS's 2025 net income turnaround to $509M from -$516M loss despite -1.2% YoY revenue to $12.5B, $3.3B debt reduction, and Aditxt Nasdaq compliance confirmation ($4M equity). Apple Hospitality reported 2025 buybacks of 5M shares, hotel portfolio optimization across 84 markets. Portfolio-level trends show sparse but improving financials (e.g., CHS EBITDA margin flat 12.2%, positive FCF), capital returns via buybacks/debt paydown/distributions, and catalysts like biotech data; implications favor monitoring leadership stability and May events amid low volatility.

12 high priority 10 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 02, 2026

Across 26 NASDAQ-100 related SEC filings dated April 2, 2026, dominant themes include a surge in proxy statements (10+ DEF/DEFA14A) signaling the onset of 2026 proxy season with clustered annual meetings in May, alongside notable executive transitions at tech leaders like Zoom (COO resignation), Alphabet (controller resignation), Broadcom (CFO retirement with Alphabet alum appointment), and Booking Holdings (new CAO). Financial highlights reveal mixed performance: Community Health Systems achieved a dramatic net income turnaround to +$509M from -$516M loss YoY despite -1.2% revenue decline, Trilogy Metals saw Q1 FY2026 loss double to $7.1M YoY amid higher expenses, Tesla reported flat +1% YoY Q1 vehicle deliveries at 358K, and Starbucks closed a positive China JV ceding 60% control for liquidity. Positive catalysts include Immunic's Phase 3 enrollment completion with topline data by end-2026, Booking's 25-for-1 stock split, and Aditxt's Nasdaq compliance resolution. Portfolio-level trends show neutral-to-positive sentiment (8 positive, 12 neutral, 4 mixed, 2 bearish implied), with healthcare/mining outliers in deteriorating losses/revenues but debt reductions/buybacks signaling capital discipline; no broad margin compression evident but limited QoQ/YOY data (e.g., Trilogy cash -7.4% QoQ, CYH EBITDA margin flat 12.2%). Implications favor monitoring May proxy votes for equity plans/governance and Q1 earnings catalysts like Tesla's April 22 webcast for deeper financials.

15 high priority 11 medium 26 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 02, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (with cross-sector exposure including REITs, financial data providers, pharma/mining outliers), sentiment is mixed with 12 positive, 14 mixed, and 10 negative summaries; period-over-period trends reveal revenue growth averaging +18% YoY in outperformers like Pharming (+26.6% to $376M), Dynaresource (+25.7% to $58M), and FactSet (+7% to $611M Q), but sharp declines in underperformers like Airsculpt (-15.8% FY to $152M), LightInTheBox (-12.2% to $224M), and Lindsay (-16% Q2 to $158M). Capital allocation emphasizes buybacks (News Corp $1B program, FactSet $303M YTD, Lindsay $25M Q2, Oceaneering $40M) and dividends (Burford 6.25¢ final), signaling shareholder returns amid volatility; M&A/SPAC activity is robust with accretive deals like Kodiak's $587M DPS acquisition (+395MW capacity) and Crown Reserve's $1B EV Carvix combo ($80M PIPE). Forward-looking catalysts cluster in May 2026 AGMs (20+ filings, e.g., Sylvamo May15, Burford May13) and guidance reaffirms (ESAB, Sally Beauty FY26); debt actions improve liquidity (Terra exchange to 2029 notes, Transocean $358M retire/$0.75B 2026 plan, CareView maturity to Jun30). Portfolio implications: overweight accretive M&A/REIT restructurings, underweight going concerns (Mannatech, Algorhythm); sector shows resilience in financial metrics (e.g., FactSet op CF +28%) despite broader declines.

28 high priority 22 medium 50 total filings